bioRxivSystems BiologyPreprint
Fusion-driven post-transcriptional network orchestrates ferroptosis resistance, dormancy, and immune remodeling in PRCC-TFE3 renal cell carcinoma
Divya MishraiD, Shivangi AgrawaliD, Divya MalikiD, Ekta PathakiD, Rajeev MishraiD
Abstract
TFE3-rearranged papillary renal cell carcinoma (pRCC) remains poorly understood due to its rarity and complex biology. By integrating matched mRNA and miRNA sequencing from the TCGA-KIRP cohort, this study reveals a fusion-specific post-transcriptional program orchestrating ferroptosis resistance, metabolic adaptation, adhesion loss, immune remodeling, and dormancy-associated signaling. Fusion-positive tumors exhibited coordinated upregulation of antioxidant and mTORC1 components (SOD2, GPX4, G6PD, NQO1, FNIP2, RRAGC), reinforced by loss of miRNA-mediated repression. In parallel, elevated miRNAs (miR-185, miR-148a, miR-130b, miR-342) suppressed MAPK, Wnt, and tight-junction genes, generating a low-proliferative, adhesion-deficient state. AGO2-compatible miRNA-mRNA structural modeling validated key duplexes, linking miRNA regulatory specificity to fusion-driven transcriptional outputs. Immune profiling revealed reduced CD3 T cells but enrichment of CD8 and NK cells, supporting a remodeled yet persistence-permissive microenvironment. Finally, connectivity mapping analysis identified candidate leads targeting the MAPK-Wnt axis. These findings define a multilayered RNA regulatory architecture unique to PRCC-TFE3 tumors.
- organism: human
- assay: bulk RNA-seq
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TFE3 fusion proteins drive oxidative metabolism, ferroptosis resistance and general RNA synthesis in translocation renal cell carcinoma
Alexandra Helleux, Guillaume Davidson, … Gabriel G. Malouf·EMBO Molecular MedicinePeer-reviewed·Mar 27, 2025
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Prathyusha Konda, Alexandra J. Wakolbinger, … Srinivas Raghavan Viswanathan·Nature CommunicationsPeer-reviewed·Aug 26, 2026
- TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma
Jiao Li, Kaimeng Huang, … Srinivas Raghavan Viswanathan·Nature MetabolismPeer-reviewed·Feb 6, 2025
- Exploring G-quadruplex structure in PRCC-TFE3 fusion Oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC)
Neha Neha, Parimal Kumar Das·bioRxiv·Jul 6, 2023
- HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma
Yilong Zou, Michael J. Palte, … Stuart L. Schreiber·bioRxiv·Aug 9, 2018
- PBRM1-VHL cooperation rewires lipid and iron metabolism to promote ferroptosis resistance in clear cell renal cell carcinoma
Guanming Jiao, Luisa F. Baracaldo-Lancheros, … Emily C. Dykhuizen·bioRxiv·May 6, 2026